Abstract
A total of 248 Gram-positive isolates from cancer patients were tested for in-vitro susceptibility to tedizolid and 3 comparator agents using CLSI broth microdilution methodology. Tedizolid inhibited 97% of isolates at ≤0.5 μg/ml. It was active against all Gram-positive species and consistently had 8 fold lower MICs than linezolid, although based on % susceptibility using CLSI breakpoints, most isolates were also susceptible to the comparators. Tedizolid was active against MRSA isolates with vancomycin MICs of ≥1.0 μg/ml.
Original language | English (US) |
---|---|
Pages (from-to) | 351-353 |
Number of pages | 3 |
Journal | Diagnostic Microbiology and Infectious Disease |
Volume | 91 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2018 |
Keywords
- Cancer patients
- Gram-positive
- In-vitro
- Tedizolid
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases